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Abstract
Introduction: Acute hemodynamic instability increases morbidity and mortality. We investigated whether early
non-invasive cardiac output monitoring enhances hemodynamic stabilization and improves outcome.
Methods: A multicenter, randomized controlled trial was conducted in three European university hospital intensive
care units in 2006 and 2007. A total of 388 hemodynamically unstable patients identified during their first six hours
in the intensive care unit (ICU) were randomized to receive either non-invasive cardiac output monitoring for 24
hrs (minimally invasive cardiac output/MICO group; n = 201) or usual care (control group; n = 187). The main
outcome measure was the proportion of patients achieving hemodynamic stability within six hours of starting the
study.
Results: The number of hemodynamic instability criteria at baseline (MICO group mean 2.0 (SD 1.0), control group
1.8 (1.0); P = .06) and severity of illness (SAPS II score; MICO group 48 (18), control group 48 (15); P = .86)) were
similar. At 6 hrs, 45 patients (22%) in the MICO group and 52 patients (28%) in the control group were
hemodynamically stable (mean difference 5%; 95% confidence interval of the difference -3 to 14%; P = .24).
Hemodynamic support with fluids and vasoactive drugs, and pulmonary artery catheter use (MICO group: 19%,
control group: 26%; P = .11) were similar in the two groups. The median length of ICU stay was 2.0 (interquartile
range 1.2 to 4.6) days in the MICO group and 2.5 (1.1 to 5.0) days in the control group (P = .38). The hospital
mortality was 26% in the MICO group and 21% in the control group (P = .34).
Conclusions: Minimally-invasive cardiac output monitoring added to usual care does not facilitate early
hemodynamic stabilization in the ICU, nor does it alter the hemodynamic support or outcome. Our results
emphasize the need to evaluate technologies used to measure stroke volume and cardiac output–especially their
impact on the process of care–before any large-scale outcome studies are attempted.
Trial Registration: The study was registered at ClinicalTrials.gov (Clinical Trials identifier NCT00354211)
Introduction
Hemodynamic instability early during intensive care
increases the risk of morbidity and mortality. Several
small studies have used pre-emptive or early hemody-
namic support protocols in septic and postoperative
patients to improve outcome [1-10]. In contrast, similar
protocols applied later have no beneficial effect and may
even worsen the outcome [11-13]. It is conceivable that
reducing the delay in stabilizing hemodynamics has the
potential for improving the subsequent clinical course.
Large-scale use of therapeutic protocols for early
intervention has been hampered by logistic and concep-
tual problems. Installing invasive hemodynamic moni-
toring is labor-intensive per se. Use of hemodynamic
management protocols assumes that appropriate goals
and interventions are known. Traditional invasive
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hemodynamic monitoring using a pulmonary artery
catheter has also been questioned [14-16].
Recently, less invasive techniques have been intro-
duced for monitoring cardiac output, stroke volume or
their surrogates [17,18]. An arterial pressure waveform-
based method allows continuous estimation of cardiac
output without calibration [19-21] and facilitates rapid
installation of minimally invasive cardiac output (MICO)
measurement in patients with an arterial line. The
MICO should reflect trends in cardiac output, even if
the absolute values may not be accurate.
We hypothesized that continuous monitoring of car-
diac output would enhance hemodynamic stabilization
in patients with unstable hemodynamics at or within
six hours of admission to the intensive care unit
(ICU). If this were true, reduced organ dysfunction
and ICU resource use and improved outcome could
be expected.
Materials and methods
This was a multicenter, international, randomized con-
trolled trial (Clinical Trials identifier NCT00354211;
ClinicalTrials.gov). Three surgical-medical university
hospital ICUs (one from Switzerland, two from Finland)
participated. All units are intensivist-led closed units
with 24-hour-a-day/7-day-a-week coverage by physicians
with duties only in the ICU.
All emergency admissions to the ICU were screened.
Patients with aortic regurgitation, with an intra-aortic
balloon pump or with a pulmonary artery catheter on
admission to ICU were excluded. All other patients at
least 18 years of age, hemodynamically unstable at or
within six hours of ICU admission, and with an arterial
line, were eligible for inclusion. Since no additional
interventions or deviations from usual care were
included, the Ethics Committees of the hospitals (Fin-
nish centers) and the Canton of Bern (Swiss center)
approved deferred written informed consent (from the
patient or the family; two centers) or deferred written
informed consent and prior to study inclusion a state-
ment of no objection to the study from an independent
physician (one center).
Hemodynamic instability was defined as the presence
of any of the following five criteria: 1) clinically relevant
hypotension (systolic arterial pressure < 90 mmHg,
acute symptomatic decrease of blood pressure, suspicion
of cerebral hypoperfusion, or acute reduction in urinary
output related to blood pressure decrease; 2) clinical
signs of hypovolemia with or without hypotension (per-
ipheral vasoconstriction, decreased venous filling); 3) oli-
guria (excluding patients with established oliguric renal
failure), with diuresis < 0.5 ml/kg estimated body
weight/hour; 4) elevated blood lactate (> 50% above
upper normal limit) and clinical suspicion of
hypoperfusion; 5) acute alteration of mental status
related to hemodynamic alterations.
Randomization and masking
The patients were randomized using fully opaque,
sequentially numbered sealed envelopes and stratifica-
tion by center to either have the MICO device (Flow-
Trac®, software version 1.07, Edwards Lifesciences,
Irvine, CA, USA) connected to their arterial pressure
measurement system (MICO group) or to serve as con-
trols (control group). The MICO device was installed by
the research staff once an arterial line was available.
In both patient groups, treatment guidelines were
made available but not enforced (see Additional file 1/
Hemodynamic guidelines). Data were collected for stan-
dard demographics, simplified acute physiology score
(SAPS) II [22], sequential organ failure assessment
(SOFA) score [23] at admission, the primary cause of
ICU admission [24], and the presence of verified or sus-
pected infection at admission. Hemodynamic data and
the five criteria of hemodynamic instability were
recorded hourly for 24 hrs, or to discharge if before 24
hrs. Fluids given for volume resuscitation (total amount,
type of fluids and their timing), vasoactive drugs, and
use of pulmonary artery catheter were recorded. In the
MICO group, the MICO device was used for the dura-
tion of hemodynamic data collection. Predicted mortal-
ities were calculated using the SAPS II coefficients [22].
Outcome criteria
The primary outcome variable was the proportion of
patients achieving hemodynamic stability within six
hours of starting the study. ICU and hospital mortality
were considered as secondary outcomes. Hospital out-
come was defined as outcome from the last of consecu-
tive hospitalizations (that is, discharges to other
hospitals) before discharge home or to rehabilitation.
ICU outcome was defined from the last ICU stay. ICU
mortality was separately analyzed post hoc for early
deaths occurring during the first 24 hrs. Further second-
ary outcomes included total time required for hemody-
namic stabilization, pulmonary artery catheter use, ICU
resource use during the primary ICU admission using
the simplified therapeutic intervention scoring system
[25] (TISS score), ICU readmissions, and length of stay
at the study institution (ICU and hospital).
Statistical analysis
(see Additional file 1 for details on statistical analysis)
The primary hypothesis was that the use of MICO
increases the proportion of patients reaching hemody-
namic stability at six hours. We assumed that 50% of
the patients from the control group would be stable at
six hours. To detect a difference of 15% in the
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proportion of patients stable at six hours with a power
of 90% at a 0.05 significance level, the minimum
required sample size was 390, with 195 in each group,
with an assumption of 5% loss of complete monitoring.
The intention-to-treat (ITT) population consisted of
all patients randomized. Patients in whom hemodynamic
assessments per protocol were not available were
excluded from the per-protocol analysis. The primary
outcome analysis for the proportion of patients stable at
six hours was done in the ITT population using the chi-
square test. Since patients could again become unstable
after initial stabilization, time needed to reach hemody-
namic stability within the first 6 hrs and 24 hrs was
further analyzed post hoc by defining the time point
after which none of the instability criteria were present
or reappeared, and by constructing separate Kaplan-
Meier curves for each time period and using the Bre-
slow test for between-group differences. Between-group
comparisons of other variables were done in the per-
protocol population. The unpaired t test or the Mann-
Whitney U-test was used for continuous variables and
the chi-square or Fisher’s exact test for proportions.
Further analyses of group and study center interactions
were done with analysis of variance. Changes from base-
line to 6 hrs and 24 hrs in stroke volume, cardiac output
and stroke volume variation in the MICO group were
analyzed using repeated measures analysis of variance
and paired t tests with Bonferroni correction. Logistic
regression was used to detect variables associated with
hospital outcome. A two-tailed P-value less than 0.05
was considered significant.
The data are shown as mean (SD) or median (25th to
75th percentile; for not normally distributed variables
according to the Kolmogorov-Smirnov test), unless spe-
cified otherwise. The statistical analyses were done with
SPSS (version 15.0, SPSS Inc., Chicago, IL, USA) and
GraphPad InStat (version 3.05; GraphPad Software, San
Diego, CA, USA).
Results
Of the 416 eligible patients, 388 patients were included
in the intention-to-treat (ITT) analysis and 386 in the
per-protocol analysis (Figure 1). The groups were com-
parable in terms of demographics (except a slightly
younger age in the MICO group and greater weight in
the control group; Table 1), type of admission (surgical
vs. medical), main admission diagnosis categories, pre-
sence of infection at admission, baseline hemodynamics,
severity of illness (Table 1), and presence of organ dys-
functions at baseline (see Additional file 1/Table 1).
Also, the time spent in the hospital before admission to
the ICU and the time from ICU admission to arterial
line insertion and study baseline were comparable
(Table 1). Sixty-one percent of patients were admitted
to the ICU within 24 hrs of hospital admission, 42%
within six hours, and 20% within one hour.
At baseline, clinical signs of hypovolemia and clinically
relevant hypotension were the most frequent criteria of
hemodynamic instability, with no significant differences
between the groups (Table 2). The number of patients
with at least three criteria of hemodynamic instability
was higher in the MICO group (P = .05; Table 2).
There were no significant differences between the
study groups in volumes or types of fluids received for
hemodynamic support in the first six hrs (Table 3). The
MICO group received slightly more colloids than the
control group after 6 hrs (P = .01) and for the whole 24
hrs (P = .01). There were no differences in the fre-
quency or type of inotropic or vasopressor drugs given,
but vasodilators were used more frequently in the con-
trol group (P = .02; Table 3). A pulmonary artery cathe-
ter was inserted in 19% of the patients in the MICO
group and in 26% in the control group (P = .11).
At six hours, 45 patients (22%) in the MICO group
and 52 patients (28%) in the control group were hemo-
dynamically stable (P = .24). In each group, 19 patients
(10%) became stable before 6 hrs and remained stable
thereafter (see Additional file 1/Table 2); 34 patients in
each group were stable at each time point (6 hrs and
24 hrs). The Kaplan-Meier curves for reaching hemo-
dynamic stability (the time point after which none of
the instability criteria were present or reappeared; see
Additional file 1/Figure 1) for 6 hrs showed no differ-
ence between the groups (P = .250). The presence of
Figure 1 Study flowchart. MICO: minimally invasive cardiac output.
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individual criteria of hemodynamic instability at base-
line and mechanical ventilation at baseline were com-
pared between stable and unstable patients at 6 hrs,
and variables with differences with a P-value less than
.10 were included in logistic regression analysis. Only
an acute symptomatic decrease in blood pressure at
baseline (P = .050) and increased blood lactate at base-
line (P = .002) were significant predictors of instability
at six hours (for additional details, see Additional file
1/Results).
Table 1 Demographics, time intervals relevant to intensive care and study admission, and baseline hemodynamics
MICO
N = 199
Control
N = 187
P-value
Age; years 59 (18) 64 (16) 0.05
Gender; n; female/male 67/132 62/125 1.00
Height; cm 171 (9) 170 (10) 0.25
Weight; kg 81 (19) 78 (18) 0.06
SAPS II 48 (18) 48 (15) 0.86
Predicted risk of death; % 43 (29) 43 (26) 0.85
Patient with > 50% risk; n 87 72 0.30
Infection, confirmed; % 27 23 0.29
Infection, suspected or confirmed; % 51 49 0.69
Surgical admission; % 32 27 0.37
Hospital admission to ICU admission; 13 13 0.49
hours (2 to 54) (1 to 93)
ICU admission to arterial line insertion; minutes 20
(6 to 45)
16
(5 to 42)
0.13
Arterial line insertion to baseline; 64 45 0.12
minutes (23-144) (17-116)
Systolic blood pressure (mmHg) 103 (26) 107 (27) 0.16
Diastolic blood pressure (mmHg) 53 (15) 53 (12) 0.95
Heart rate (beats/min) 97 (24) 95(25) 0.40
APACHE III diagnostic groups (%) 0.56
Medical admission
Cardiovascular 17.1 23.0 0.16
Respiratory 14.1 18.2 0.33
Gastrointestinal 10.1 8.6 0.73
Sepsis 14.6 11.2 0.37
Other medical 12.6 11.8 0.88
Surgical admission
Cardiovascular 5.5 7.5 0.54
Gastrointestinal 13.1 8.6 0.19
Trauma 4.5 4.8 1.00
Other surgical 8.5 6.4 0.45
Values are mean (SD), median (25th to 75th percentile), ratio, or percentage, as indicated.
APACHE, acute physiology and chronic health evaluation; MICO, minimally invasive cardiac output; SAPS II, simplified acute physiology score II.
Table 2 Presence of criteria for hemodynamic instability at baseline
MICO
n = 199
Control
n = 187
P-value
Clinically relevant hypotension; n (%) 109 (55) 87 (47) .13
Clinical signs of hypovolemia; n (%) 134 (67) 124 (66) .91
Oliguria; n (%) 71 (36) 50 (27) .06
Elevated blood lactate; n (%) 59 (30) 48 (26) .43
Acute changes in mental status related to hemodynamics; n (%) 23 (12) 26 (14) .54
Number of instability criteria; mean (SD) 2.0 (1.0) 1.8 (1.0) .06
Number of patients with at least three criteria; n (%) 60 (30) 40 (21) .05
MICO, minimally invasive cardiac output; SD, standard deviation.
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In the MICO group, stroke volume increased margin-
ally [baseline: 65 mL (20 mL), 6 hrs: 65 mL (20 mL), 24
hrs: 69 mL (20 mL); P = .002] and stroke volume varia-
tion decreased slightly over time (baseline: 16% (12%); 6
hrs: 15% (10%); 24 hrs: 14% (10%): P = .05), whereas
cardiac output did not change significantly (baseline: 5.9
(2.0) L/minute, 6 hrs: 5.9 (1.8) L/minute; 24 hrs: 6.1
(1.8) L/minute: P = .23].
Neither the ICU mortality nor the hospital mortality
was significantly different between the groups (ICU
mortality MICO 18%, control 12%, P = .122, relative
risk = 1.497
95% confidence interval 0.925 to 2.42; hospital mortal-
ity MICO 26%, control 21%, P = .34, risk = 1.209, 95%
confidence interval .843 to 1.735). There were more
deaths from randomization until 24 hrs after end of
study monitoring in the MICO group (MICO n = 16 vs.
control n = 4, P = .011). All but one of these deaths (in
the MICO group) occurred after withdrawal of treat-
ment due to poor prognosis of the underlying condition
(for details, see Additional file 1/Table 3).
The 24-hr Kaplan-Meier curves (Figure 2) indicated
that patients in the control group were more likely to
reach hemodynamic stability (P = .033). After excluding
the early deaths, the difference was not significant (P =
.11). When stratified according to number of instability
criteria at baseline (≥ 3 vs. < 3 criteria), the difference
between MICO and control groups was not significant
(P = .79 for ≥ 3 criteria; P = .12 for < 3 criteria).
Differences between survivors and non-survivors were
tested for study group, presence of each of the indivi-
dual criteria of hemodynamic instability at baseline and
6 hrs, mechanical ventilation at baseline and 6 hrs, sta-
bility at 6 hrs and 24 hrs, and time to achieve hemody-
namic stability. Those with a P-value less than .10 were
included in logistic regression analysis. Only oliguria (P
= .000) and increased lactate (P = .01) at baseline were
significant predictors of hospital mortality (for additional
details, see Additional file 1/Results and Additional file
1/Tables 4-8).
Resource utilization was similar in the two groups.
The TISS score for the first 24 hrs in the ICU was 32
(8) in the MICO group and 32 (9) in the control group
(P = .79). The sum of TISS scores for the whole ICU
stay was 172 (215) in the MICO group and 174 (194) in
the control group (P = .93). The median length of stay
in the ICU was 2.0 (1.2 to 4.6) days in the MICO group
and 2.5 (1.1 to 5.0) days in the control group (P = .38).
The duration from ICU admission to hospital discharge
was 11.0 (5.6 to 18.3) days in the MICO group and 10.4
(5.3 to 18.6) days in the control group (P = .78).
Twenty-three patients (11%) in the MICO group and 29
(16%) in the control group were later readmitted to the
ICU (P = .30).
Table 3 Hemodynamic support with fluids and vasoactive
drugs
MICO
n = 199
Control
n = 187
P-
value
Volume replacement; mL/
kg
Total
0 to 6 hrs 11.4 (5.0 to 20.9) 9.1 (2.7 to 19.5) .22
7 to 24 hrs 14.2 (5.6 to 28.2) 13.2 (5.4 to 29.4) .76
0 to 24 hrs 28.6 (16.3 to
45.8)
24.9 (15.0 to
48.0)
.40
Colloids
0 to 6 hrs 5.8 (0.0 to 12.1) 4.9 (0.0 to 9.7) .33
7 to 24 hrs 6.7(1.9 to 14.8) 5.7 (0.0 to 13.0) .06
0 to 24 hrs 14.9 (6.7 to 22.1) 11.0 (5.6 to 23.3) .09
Crystalloids
0 to 6 hrs 0.0 (0.0 to 8.0) 0.0 (0.0 to 7.0) .54
7 to 24 hrs 0.0 (0.0 to 11.0) 0.0 (0.0 to 13.0) .58
0 to 24 hrs 6.0 (0.0 to 22.0) 6.0 (0.0 to 20.0) .81
Blood products
0 to 6 hrs 0.0 (0.0 to 4.0) 0.0 (0.0 to 3.0) .76
7 to 24 hrs 0.0 (0.0 to 0.0) 0.0 (0.0 to 0.0) .62
0 to 24 hrs 0.0 (0.0 to 6.0) 0.0 (0.0 to 7.0) .64
Any vasoactive drug 150 (75) 150 (80) .27
dobutamine 44 (22) 45 (24) .72
noradrenaline 115 (58) 103 (55) .61
adrenaline 19 (10) 14 (7) .59
vasodilator 26 (13) 42 (22) .02
beta-blocking agents 6 (3) 14 (7) .07
other anti-arrhythmic
drugs
14 (7) 23 (12) .09
Fluids given for basal daily needs of water and electrolytes (maintenance
fluids) excluded. Values are median (interquartile range) for fluids and number
of patients (percentage) receiving vasoactive drugs.
MICO, minimally invasive cardiac output.
Figure 2 Hemodynamic stability (P = 0.033) and cumulative
occurrence of deaths within the first 24 hrs. MICO: minimally
invasive cardiac output.
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Discussion
The main finding of the study was that providing contin-
ual cardiac output and stroke volume monitoring non-
invasively during treatment of hemodynamic instability
did not increase the proportion of patients achieving
hemodynamic stability during the early phase of treat-
ment. The use of fluids and catecholamines was very
similar in the two study groups, suggesting that the avail-
ability of additional hemodynamic information did not
change the treatment as compared to standard therapy.
Given the similarity of treatments received, and assuming
that the severity and main characteristics of the underly-
ing clinical problems also reflected similar pathophysiol-
ogy of hemodynamic instability in both groups, it should
be expected that the main clinical outcomes were not dif-
ferent. Our assumption that the availability of more
information would help to accelerate hemodynamic sta-
bilization is clearly not supported by the results.
Hemodynamic monitoring in intensive care has been
controversial over the past decades. Use of the pulmon-
ary artery catheter has markedly decreased due to stu-
dies suggesting that its routine use does not improve
clinically relevant outcomes [14-16,26-31], and the costs
associated with its use are substantial. Nevertheless,
early hemodynamic instability is indisputably a risk fac-
tor for poor outcome [32-35]. Accordingly, alternative
techniques for hemodynamic monitoring have been
introduced and adopted for widespread clinical use
despite the lack of proof of efficacy and despite the
costs involved [17-21,36].
We chose to use the proportion of patients stable at
six hours, an outcome reflecting the care process, as the
primary outcome variable, because early treatment of
hemodynamic instability has been perceived as crucial
for improving outcome. If this cannot be achieved, any
improvements in other outcomes are unlikely.
Our study can be criticized due to the lack of a treat-
ment protocol combined with the use of a monitoring
device - a feature that is common to most previous stu-
dies on hemodynamic monitoring, especially those on
the pulmonary artery catheter [15,16]. Several single-
center and small-scale studies have shown improved
clinically relevant outcomes when hemodynamic moni-
toring has been combined with the use of protocols to
guide treatment [1-10]. Protocolized care is problematic
for various reasons, such as difficulties in defining the
“right” intervention, acceptance in routine clinical use,
compliance, and efficacy outside clinical trials. Further-
more, new monitoring devices are normally introduced
into clinical practice without the use of proven protocols
to achieve efficacy.
Despite the lack of protocol use in our study, almost
half of the fluids were given during the first six hours,
suggesting more intensive treatment during the early
ICU stay. We further evaluated (data not shown)
patients receiving little fluids for volume expansion dur-
ing the first six hours (< 5 ml/kg); most of these had
either a cardiac or respiratory (APACHE III diagnoses
cardiac arrest, cardiac failure, acute myocardial infarc-
tion, bacterial or aspiration pneumonia) cause for ICU
admission, which is likely to explain the restrictive
volume supply, or were admitted postoperatively having
already received treatment.
We expected that rapid availability of stroke volume
and cardiac output at the bedside would help clinicians
select interventions resulting in enhanced stabilization.
There are several possible reasons why this failed. The
reliability and accuracy of arterial pulse wave-based
stroke volume and cardiac output technologies to track
changes can be questioned [20,21,37]. Hence, the clini-
cians possibly did not trust the information. Indirectly,
more frequent use of the pulmonary artery catheter to
gain more hemodynamic data in the control group
speaks against this. All participating centers had 24-
hour-a-day, 7-day-a-week in-unit coverage by intensive
care physicians, and all centers used invasive hemody-
namic monitoring routinely. This may have facilitated
the care process in both groups, and any potential
improvements would be difficult to achieve. We con-
sider this explanation unlikely, despite the substantially
lower than expected hospital mortality (MICO 26% vs.
44%, control 21% vs. 43%). Despite the high physician
coverage, the proportion of patients who became hemo-
dynamically stable within 6 hrs and remained stable was
low (only 10% in both groups), and less than half of the
patients reached stability within 24 hrs. This was clearly
less than expected in our power calculations, and would
have reduced the chance of finding any difference. The
lower than expected statistical power is probably not
relevant, because not even a numeric trend in favor of
MICO was seen for any relevant outcome. More impor-
tantly, the low rate of reaching stability suggests that the
care process could have been improved. We consider
that our results provide another example of the difficul-
ties in changing clinical practice. In the future, combin-
ing such technologies with care protocols should be
tested.
Patients in the control group were more likely to
achieve hemodynamic stability at 24 hrs than patients in
the MICO group. Despite lack of differences in achiev-
ing stability at six hours and in-hospital mortality, the
possibility that stroke volume and cardiac output data
delayed interventions should be considered. The similar-
ity of the treatments, including the marginally higher
use of colloids after six hours in the MICO group,
speaks against this. The more frequent use of
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vasodilators in the control group is also unlikely to
explain the difference at 24 hrs due to the small number
of patients with vasodilators. Also, there were no differ-
ences between the groups in the frequency of each of
the hemodynamic instability criteria in patients still in
the ICU at 24 hrs (see Additional file 1/Tables 3-7).
Subtle differences in the case mix are more likely to
explain this result, especially the substantially higher
number of patients in the MICO group who died early
after discontinuation of treatment due to poor prognosis
of the underlying disease. Most importantly, these early
deaths in the MICO group markedly increased the pro-
portion of patients unstable at 24 hrs. In addition,
patients in the MICO group tended to have more
instability criteria at baseline (P = .06), and more MICO
patients had at least three instability criteria, suggesting
more severe illness at baseline.
Our study has additional limitations. Results obtained
with a specific device for stroke volume and cardiac out-
put monitoring should not be generalized. The specific
MICO technology used in the present study has been
associated with problems of accuracy, especially in high
cardiac output states [21,37], and newer software ver-
sions have been developed to address this [37,38]. Our
results emphasize the need to evaluate these technolo-
gies - especially their impact on the process of care -
before any large-scale outcome studies are attempted.
The study centers had very high physician coverage,
which may be rather exceptional. It is conceivable that
the effect on process of care may be highly dependent
on staff availability and presence.
Conclusions
In a heterogeneous population of hemodynamically
unstable critically ill patients, early, non-invasive continu-
ous cardiac output monitoring did not shorten the time
to reach hemodynamic stability, produce any outcome
benefit, or reduce the amount of resources used during
the ICU stay as compared to standard treatment. The
similarity of treatments received in both groups suggests
that the availability of cardiac output data did not change
the care process. Our results do not exclude the possibi-
lity that this device, when combined with a specific care
protocol or used in other circumstances or with other
non-invasive continuous cardiac output monitoring tech-
nologies, could have an impact on relevant outcomes.
Future trials should test whether non-invasive cardiac
output monitoring combined with a treatment protocol
can shorten the time to reach hemodynamic stability.
Key messages
• Only a minority of patients (22% in the MICO
group and 28% in usual care) could be stabilized in
the first six hours in the ICU.
• MICO did not facilitate hemodynamic stabilization
during the first 24 hrs of intensive care.
• Additional monitoring with MICO per se had no
effect on the care process (additional monitoring,
fluid and vasoactive therapy).
• MICO should be tested in combination with treat-
ment protocols to enhance early hemodynamic stabi-
lization in the intensive care environment.
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